33.62

0.63% 0.21

After Hours: 33.62

Alkermes Plc (ALKS)

Overview News Price History Option Chain Financials Why ALKS Down? Discussions Forecast Stock Split

Alkermes Plc stock is traded at $33.62, with a volume of 1.50M. It is up +0.63% in the last 24 hours and down -6.61% over the past month. Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Previous Close:

$33.41

Open:

$33.08

24h Volume:

1.50M

Relative Volume:

0.95

Market Cap:

$5.47B

Revenue:

$1.51B

Net Income/Loss:

$333.35M

P/E Ratio:

17.24

EPS:

1.95

Net Cash Flow:

$315.22M

1W Performance:

-2.97%

1M Performance:

-6.61%

6M Performance:

+21.55%

1Y Performance:

+16.78%

1-Day Range:

$33.01

$34.00

1-Week Range:

$33.01

$35.58

52-Week Range:

$22.90

$36.45

Alkermes Plc Stock (ALKS) Company Profile

Name

Alkermes Plc

Sector

Healthcare (1169)

Industry

Drug Manufacturers - Specialty & Generic (1)

Phone

00-353-1-772-8000

Address

CONNAUGHT HOUSE, DUBLIN 4

Employee

1,800

Twitter

@alkermes

Next Earnings Date

2024-10-24

Latest SEC Filings

ALKS's Discussions on Twitter

Compare ALKS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALKS Alkermes Plc	33.62	5.47B	1.51B	333.35M	315.22M	1.95
ZTS Zoetis Inc	160.06	71.67B	9.26B	2.49B	2.30B	5.47
TAK Takeda Pharmaceutical Co Adr	15.03	47.44B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	10.19	46.08B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	16.46	18.86B	16.54B	-1.64B	749.00M	-1.45
ITCI Intra Cellular Therapies Inc	131.36	13.97B	612.78M	-86.37M	-62.91M	-0.87

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-04-25	Upgrade	UBS	Sell → Neutral
Feb-11-25	Initiated	Deutsche Bank	Buy
Nov-05-24	Upgrade	Stifel	Hold → Buy
Jun-17-24	Initiated	TD Cowen	Buy
Mar-19-24	Initiated	Robert W. Baird	Outperform
Feb-20-24	Downgrade	UBS	Neutral → Sell
Nov-20-23	Resumed	JP Morgan	Neutral
Oct-24-23	Upgrade	Evercore ISI	In-line → Outperform
Oct-17-23	Initiated	UBS	Neutral
Nov-03-22	Upgrade	Piper Sandler	Neutral → Overweight
Oct-14-22	Upgrade	BofA Securities	Underperform → Neutral
Aug-16-22	Initiated	Piper Sandler	Neutral
Apr-22-22	Resumed	Goldman	Buy
Apr-20-22	Initiated	Goldman	Buy
Jan-27-22	Upgrade	Cantor Fitzgerald	Hold → Overweight
Dec-01-21	Initiated	Citigroup	Neutral
Oct-07-21	Upgrade	Jefferies	Hold → Buy
Sep-02-21	Downgrade	BofA Securities	Neutral → Underperform
Oct-15-20	Upgrade	Mizuho	Neutral → Buy
Jul-30-20	Downgrade	Goldman	Neutral → Sell
Feb-14-20	Downgrade	BofA/Merrill	Buy → Neutral
Feb-14-20	Reiterated	H.C. Wainwright	Neutral
Feb-14-20	Downgrade	JP Morgan	Overweight → Neutral
Feb-06-20	Initiated	Mizuho	Neutral
Jan-31-20	Upgrade	Wolfe Research	Underperform → Peer Perform
Sep-05-19	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jul-15-19	Upgrade	Goldman	Sell → Neutral
May-31-19	Initiated	H.C. Wainwright	Neutral
May-01-19	Downgrade	Citigroup	Buy → Neutral
Dec-19-18	Downgrade	Goldman	Neutral → Sell
Dec-14-18	Initiated	Wolfe Research	Underperform
Dec-13-18	Downgrade	Credit Suisse	Outperform → Underperform
Nov-05-18	Initiated	Piper Jaffray	Neutral
Aug-07-18	Initiated	Stifel	Hold
Jun-21-18	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Jun-06-18	Initiated	B. Riley FBR, Inc.	Buy
May-16-18	Upgrade	Citigroup	Neutral → Buy
May-11-18	Initiated	BofA/Merrill	Buy

View All

Alkermes Plc Stock (ALKS) Latest News

Mar 13, 2025

Alkermes Facing Near-Term Headwinds Across Existing Franchises, Royalties, RBC Says - Marketscreener.com

Mar 13, 2025

S&P 500 Futures Drop in Premarket Trading; Alkermes, Intel Lead - Barron's

Mar 13, 2025

Alkermes initiated with a Sector Perform at RBC Capital - TipRanks

Mar 13, 2025

Charles Schwab Investment Management Inc. Sells 38,088 Shares of Alkermes plc (NASDAQ:ALKS) - Defense World

Mar 13, 2025

Mar 12, 2025

Alkermes at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights - Investing.com India

Mar 12, 2025

Alkermes to Participate in Upcoming Investor Conferences - GuruFocus.com

Mar 12, 2025

Mar 09, 2025

Alkermes Plc to Host Earnings Call - ACCESS Newswire

Mar 09, 2025

Alkermes plc (NASDAQ:ALKS) Shares Bought by Smartleaf Asset Management LLC - Defense World

Mar 09, 2025

Proficio Capital Partners LLC Buys New Stake in Alkermes plc (NASDAQ:ALKS) - Defense World

Mar 09, 2025

Mar 08, 2025

Y Intercept Hong Kong Ltd Invests $413,000 in Alkermes plc (NASDAQ:ALKS) - MarketBeat

Mar 06, 2025

Mar 05, 2025

UBS Upgrades Alkermes (ALKS) - Nasdaq

Mar 05, 2025

Bank of New York Mellon Corp Has $61.45 Million Stock Holdings in Alkermes plc (NASDAQ:ALKS) - Defense World

Mar 05, 2025

Alkermes (NASDAQ:ALKS) Upgraded to Neutral at UBS Group - Defense World

Mar 05, 2025

Mar 04, 2025

UBS Upgrades Alkermes to Neutral From Sell, $38 Price Target -March 04, 2025 at 08:27 am EST - Marketscreener.com

Mar 04, 2025

Alkermes upgraded to Neutral from Sell at UBS - TipRanks

Mar 04, 2025

Mar 01, 2025